摘要
目的探讨不可切除肺鳞癌患者采用支气管动脉化疗栓塞(bronchial artery chemoembolization,BACE)联合化疗方案治疗的临床效果。方法选取2022年10月—2024年6月山东大学第三人民医院收治的不可切除肺鳞癌患者72例为研究对象,以随机数字表法分成研究组(n=36)与对照组(n=36),对照组采用化疗方案治疗,研究组采用BACE联合化疗方案治疗,比较2组近期疗效、肿瘤标志物水平、不良反应发生率。结果研究组客观有效率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)分别为61.11%、94.44%,高于对照组的36.11%、75.00%,差异有统计学意义(P<0.05)。2组治疗前糖类抗原199(carbohydrate antigen 199,CA199)[(42.71±6.83)μg/L vs.(43.29±7.05)μg/L]、癌胚抗原(carcinoembryonic antigen,CEA)[(6.02±1.68)μg/L vs.(5.85±1.56)μg/L]、糖类抗原125(carbohydrate antigen 125,CA125)[(41.86±6.78)U/mL vs.(42.13±6.82)U/mL]、鳞状细胞癌抗原(squamous cell carcinoma antigen,SCCA)[(3.58±0.96)ng/mL vs.(3.62±1.03)ng/mL]、细胞角蛋白19片段抗原21-1(cytokeratin-19-fragment antigen 21-1,CYFRA21-1)[(5.75±1.15)ng/mL vs.(5.86±1.21)ng/mL]水平对比差异无统计学意义(P>0.05)。研究组治疗后CA199、CEA、CA125、SCCA、CYFRA21-1水平分别为(21.06±5.37)μg/L、(2.66±0.57)μg/L、(13.81±4.15)U/mL、(1.84±0.62)ng/mL、(2.03±0.25)ng/mL,较治疗前降低,且低于对照组的(25.14±5.52)μg/L、(3.32±0.59)μg/L、(18.42±5.07)U/mL、(2.19±0.71)ng/mL、(2.64±0.38)ng/mL,差异有统计学意义(P<0.05)。研究组不良反应发生率为22.22%,低于对照组的47.22%,差异有统计学意义(P<0.05)。结论不可切除肺鳞癌患者采用BACE联合化疗方案治疗能够提高近期疗效,改善肿瘤标志物水平,并降低不良反应发生率。
Objective To explore the clinical effect of bronchial artery chemoembolization(BACE)combined with chemotherapy regimen in patients with unresectable lung squamous cell carcinoma.Methods A total of 72 patients with unresectable lung squamous cell carcinoma admitted to Jinan Third People's Hospital from October 2022 to June 2024 were selected as the research subjects.They were divided into the study group(n=36)and the control group(n=36)by random number table method.The control group was treated with chemotherapy regimens,while the study group was treated with BACE combined with chemotherapy regimens.The short-term efficacy,tumor marker levels and incidence of adverse reactions were compared between the two groups.Results The objective response rate(ORR)and disease control rate(DCR)of the study group were 61.11%and 94.44%respectively,which were higher than 36.11%and 75.00%of the control group,the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences between the two groups in carbohydrate antigen 199(CA199)[(42.71±6.83)μg/L vs.(43.29±7.05)μg/L],carcinoembryonic antigen(CEA)[(6.02±1.68)μg/L vs.(5.85±1.56)μg/L],carbohydrate antigen 125(CA125)[(41.86±6.78)U/mL vs.(42.13±6.82)U/mL],squamous cell carcinoma antigen(SCCA)[(3.58±0.96)ng/mL vs.(3.62±1.03)ng/mL]or cytokeratin-19 fragment antigen 21-1(CYFRA21-1)[(5.75±1.15)ng/mL vs.(5.86±1.21)ng/mL]levels(P>0.05).After treatment,the levels of CA199,CEA,CA125,SCCA and CYFRA21-1 in the study group were(21.06±5.37)μg/L,(2.66±0.57)μg/L,(13.81±4.15)U/mL,(1.84±0.62)ng/mL and(2.03±0.25)ng/mL respectively,which were decreased compared with those before treatment and were lower than those of the control group[(25.14±5.52)μg/L,(3.32±0.59)μg/L,(18.42±5.07)U/mL,(2.19±0.71)ng/mL,(2.64±0.38)ng/mL],and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 22.22%,which was lower than 47.22%in the control group,and the difference was statistically significant(P<0.05).Conclusion The treatment of patients with unresectable lung squamous cell carcinoma using the BACE combined with chemotherapy regimen can improve the short-term efficacy,improve the levels of tumor markers,and reduce the incidence of adverse reactions.
作者
王银昌
张圣村
王峰
WANG Yinchang;ZHANG Shengcun;WANG Feng(Department of Interventional,Jinan Third People's Hospital,Jinan Shandong 250132,China;Department of Comprehensive Therapy,Jinan Third People's Hospital,Jinan Shandong 250132,China)
出处
《中国卫生标准管理》
2025年第13期106-110,共5页
China Health Standard Management
关键词
不可切除肺鳞癌
化疗方案
支气管动脉化疗栓塞
临床效果
肿瘤标志物
不良反应
unresectable lung squamous cell carcinoma
chemotherapy regimen
bronchial artery chemoembolization
clinical efficacy
tumor markers
adverse reactions
